3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
7
Triple Negative Breast Neoplasms
5
Neoplasms
4
Ovarian Neoplasms
3
Pancreatic Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Zollinger-Ellison Syndrome
1
Vipoma
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pheochromocytoma
1
Pathologic Complete Response
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 2b
1
Multiple Endocrine Neoplasia Type 2a
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Liver Neoplasms
1
Insulinoma
1
Hemangiosarcoma
1
Glucagonoma
1
Gliosarcoma
1
Glioblastoma
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
4
Trastuzumab
4
Oxaliplatin
4
Fluorouracil
4
Cyclophosphamide
4
Carboplatin
4
Radiotherapy
3
Paclitaxel
3
Endoscopy
3
Docetaxel
3
Cytarabine
3
Chemoradiotherapy
3
Capecitabine
3
toripalimab
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Observation
2
Neoadjuvant Therapy
2
Metformin
2
Magnetic Resonance Imaging
2
Leucovorin
2
Irinotecan
2
Immunotherapy
2
Immune Checkpoint Inhibitors
2
Epirubicin
2
Drug Therapy
2
Doxorubicin
2
Cisplatin
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pathologic Complete Response
×
veliparib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled